Hanmi Pharmaceutical challenges invalidity of patent for Ezetrol… A war for exclusive rights has begun
Hanmi Pharmaceutical will challenge nullity of patent for compositions of Merck’s Ezetrol(Ezetimibe), medication for hyperlipidemia.
People’s attention has been drawn to whether the challenge for the nullity would effect on preferred sales product authority followed by the patent linkage system ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
